Risankizumab

CONTENTS

4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 risankizumab : Crohn’s disease
19 risankizumab : Psoriasis

LIST OF FIGURES
13 Figure 22: Datamonitor Healthcare’s drug assessment summary of Incruse for COPD
16 Figure 14: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country, 2017–26
24 Figure 24: Datamonitor Healthcare’s drug assessment summary of Seebri Neohaler for COPD

LIST OF TABLES
5 Table 1: Risankizumab drug profile
7 Table 2: Risankizumab Phase III trials in Crohn’s disease
11 Table 3: Risankizumab Phase II data in Crohn’s disease
17 Table 4: Risankizumab sales for Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016–25
20 Table 5: Risankizumab drug profile
21 Table 6: Risankizumab late-phase trials in psoriasis
22 Table 7: Phase II results from risankizumab’s head-to-head trial against Stelara